Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of PF-08634404 plus chemotherapy versus bevacizumab plus chemotherapy in untreated metastatic colorectal cancer
CTR20261846Phase 3Active
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PF-08634404, bevacizumab in colorectal cancer (CRC), sponsored by Pfizer. Started Jun 2026; status: active.
02
Drugs
PF-08634404bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20261846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261846.